Balchem Corp. Q1 2009 Financial Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2009. Balchem Corporation develops, manufactures, and distributes specialty performance ingredients for the food, nutritional, pharmaceutical, animal health, and medical device sterilization industries. The company operates through three segments: Specialty Products, Food, Pharma & Nutrition, and Animal Nutrition & Health.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $52,986 | $56,861 |
| Gross Margin | $16,298 (30.8%) | $13,483 (23.7%) |
| Operating Income | $9,310 (17.6%) | $7,404 (13.0%) |
| Net Earnings | $6,098 | $4,641 |
| Diluted EPS | $0.32 | $0.25 |
| Operating Cash Flow | $18,502 | $7,232 |
| Cash & Equivalents (End) | $18,553 | $3,922 |
| Total Debt (Current + Long-term) | $9,226 | N/A |
| Working Capital | $38,319 | N/A |
Note: Debt figures represent the sum of current portion of long-term debt, revolver borrowings, and long-term debt as of March 31, 2009.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6.8% to $52.99 million, driven by volume declines in the Food, Pharma & Nutrition segment (-10.6%) and Animal Nutrition & Health segment (-8.3%) due to the global economic downturn and customer inventory management. Specialty Products sales increased 4.1%.
- Profitability Expansion: Despite lower sales, Net Earnings increased 31.4% to $6.10 million. Operating margins improved from 13.0% to 17.6% primarily due to significant reductions in petro-chemical raw material costs and favorable product mix.
- Strong Cash Generation: Operating cash flow more than doubled to $18.5 million, fueled by higher net earnings and a $4.4 million reduction in accounts receivable.
- Debt Reduction: The company prepaid the remaining balance ($867k) of its $29 million Term Loan during the quarter. Total debt load decreased significantly compared to the prior year.
Outlook, Risks, and Management Commentary
- Outlook: Management continues to focus on productivity improvements and growth through new product development, specifically citing the launch of AminoShure-L (rumen-protected lysine). The company is actively pursuing acquisition candidates.
- Liquidity: Cash and cash equivalents increased to $18.55 million. The company maintains a $6 million U.S. revolving facility (currently unused) and a European revolving facility with $1.915 million drawn. Management believes existing facilities will be renewed in the normal course of business.
- Risks: The company faces exposure to foreign currency exchange rates and commodity price risks for raw materials. While the company manages these through pricing and operational means, the global economic downturn continues to impact demand in the poultry and industrial sectors.
- Contingencies: The company is involved in ongoing environmental monitoring at its Slate Hill, NY site (costs <$5k/year) and maintains capped areas at its Verona, MO facility (indemnified by prior owner). No material litigation is expected to impact financial position.
Investor Verification Checklist
- Verify the sustainability of the 30.8% gross margin given the volatility of petro-chemical raw material prices.
- Monitor the renewal status of the European Revolving Facility and Term Loan maturing in May 2010.
- Assess the impact of the strengthening U.S. dollar on international sales, particularly in the Animal Nutrition segment.
- Review the progress of new product launches (e.g., AminoShure-L) to offset volume declines in traditional choline and calcium products.
- Confirm the status of the stock repurchase program, which has been inactive since the inception of the current quarter.